Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2008 December;56(6) > Minerva Cardioangiologica 2008 December;56(6):671-92

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA CARDIOANGIOLOGICA

A Journal on Heart and Vascular Diseases


Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,752


eTOC

 

REVIEWS  


Minerva Cardioangiologica 2008 December;56(6):671-92

Hypertrophic cardiomyopathy: individualized therapy for a heterogeneous disease

M. V. Sherrid, T. Sirak

Hypertrophic Cardiomyopathy Program and the Echocardiography Laboratory Division of Cardiology, Department of Medicine
St. Luke’s, Roosevelt Hospital Center Columbia University College of Physicians and Surgeons New York City, NY, USA


PDF  


It is now 50 years since the modern description of hypertrophic cardiomyopathy (HCM). The initial descriptions foretold the current efforts towards sudden death prevention, alleviation of heart failure symptoms and angina, relief of left ventricular outflow tract obstruction, preparticipation athletic screening, family screening and genetic testing. The authors review the salient features of HCM, focusing on therapeutic strategies to manage its symptoms and attempts to prevent sudden death.

top of page

Publication History

Cite this article as

Corresponding author e-mail